Literature DB >> 33407294

An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan.

Umar Farooq Bullo1, Jaishri Mehraj2,3, Syed Musa Raza1,4, Shumaila Rasool1,5, Noreen Naz Ansari1, Ahmed Ali Shaikh1,6, Zamir Ali Phul1,5, Sohail Ahmed Memon1,5, Rehan Iqbal Baloch1, Zahoor Ahmed Baloch7, Shoukat Ali Chandio1,4.   

Abstract

BACKGROUND: Inactivated Polio Vaccine (IPV) campaign was conducted in February 2019 in Karachi where needle-free injectors were introduced for the administration of the fractional dose of IPV (fIPV) on a large scale. This study aimed to determine the impact of needle-free injectors on vaccination coverage.
METHODS: In four towns of Karachi, fIPV was given using needle-free injectors "PharmaJet Tropis ID". Whereas, in six towns full dose of IPV was administered to children of 4-59 months of age. Cluster surveys through rapid convenience assessment method were conducted after the completion of vaccination activity.
RESULTS: A total of 33,815 households' data was analyzed. Among these, 27,650 (82.8%) children were vaccinated. In fIPV areas, 85.3% of children were vaccinated compared to 79.5% in full dose IPV areas. A comparison of reasons for unvaccinated showed that 1.6% of parents do not give importance to vaccination in fIPV areas compared to 4.2% in full IPV areas (p-value < 0.0001). More children were not vaccinated due to fear of injection 1.8% in full IPV areas compared to 0.7% in fIPV areas (p-value < 0.0001). The source of campaign information shows that more frequent mobile miking 3.1% was observed in fIPV areas compared to 0.4% in full IPV areas (p-value < 0.0001).
CONCLUSIONS: Our analysis supports the fractional dose of IPV in mass campaigns to achieve good vaccination coverage especially using needle-free injectors "PharmaJet Tropis ID" and vigorous social mobilization activities are expedient in accomplishing high coverage.

Entities:  

Keywords:  Campaign; Fractional dose; Inactivated polio vaccine; Pakistan; Vaccination

Year:  2021        PMID: 33407294      PMCID: PMC7789602          DOI: 10.1186/s12889-020-10041-8

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  20 in total

1.  Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba.

Authors:  Sonia Resik; Alina Tejeda; Pedro Mas Lago; Manuel Diaz; Ania Carmenates; Luis Sarmiento; Nilda Alemañi; Belkis Galindo; Anthony Burton; Martin Friede; Mauricio Landaverde; Roland W Sutter
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

2.  Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-05-29

3.  Fractional doses of inactivated poliovirus vaccine in Oman.

Authors:  Ali Jafer Mohammed; Salah AlAwaidy; Shyam Bawikar; Padmamohan J Kurup; Emadaldin Elamir; Mahmoud M A Shaban; Sharif M Sharif; Harrie G A M van der Avoort; Mark A Pallansch; Pradeep Malankar; Anthony Burton; Meghana Sreevatsava; Roland W Sutter
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Parents' hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia.

Authors:  Amanda Yufika; Abram Luther Wagner; Yusuf Nawawi; Nur Wahyuniati; Samsul Anwar; Fitria Yusri; Novi Haryanti; Nanda Putri Wijayanti; Rizal Rizal; Devi Fitriani; Nurul Fadhliati Maulida; Muhammad Syahriza; Ikram Ikram; Try Purwo Fandoko; Muniati Syahadah; Febrivan Wahyu Asrizal; Alma Aletta; Sotianingsih Haryanto; Kurnia Fitri Jamil; Mudatsir Mudatsir; Harapan Harapan
Journal:  Vaccine       Date:  2020-02-01       Impact factor: 3.641

5.  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

6.  Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial.

Authors:  Muhammad Atif Habib; Sajid Soofi; Simon Cousens; Saeed Anwar; Najib Ul Haque; Imran Ahmed; Noshad Ali; Rehman Tahir; Zulfiqar A Bhutta
Journal:  Lancet Glob Health       Date:  2017-06       Impact factor: 26.763

7.  Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016.

Authors:  George Shirreff; Mufti Zubair Wadood; Rui Gama Vaz; Roland W Sutter; Nicholas C Grassly
Journal:  Emerg Infect Dis       Date:  2017-02-15       Impact factor: 6.883

8.  Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.

Authors:  Kamal Fahmy; Lee M Hampton; Houda Langar; Manish Patel; Tahir Mir; Chandrasegarar Soloman; Andreas Hasman; Nasir Yusuf; Nadia Teleb
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

9.  Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Authors:  Deepa Gamage; Ondrej Mach; Samitha Ginige; William C Weldon; M Steven Oberste; Visalakshi Jeyaseelan; Roland W Sutter
Journal:  J Infect Dis       Date:  2019-05-24       Impact factor: 7.759

10.  Combined use of inactivated and oral poliovirus vaccines in refugee camps and surrounding communities - Kenya, December 2013.

Authors:  Mohamed A Sheikh; Frederick Makokha; Abdullahi M Hussein; Gedi Mohamed; Ondrej Mach; Kabir Humayun; Samuel Okiror; Leila Abrar; Orkhan Nasibov; John Burton; Ahmed Unshur; Kathleen Wannemuehler; Concepcion F Estivariz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-03-21       Impact factor: 17.586

View more
  1 in total

Review 1.  Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.

Authors:  Birgitte Giersing; Natasha Shah; Debra Kristensen; Jean-Pierre Amorij; Anna-Lea Kahn; Kristoffer Gandrup-Marino; Courtney Jarrahian; Darin Zehrung; Marion Menozzi-Arnaud
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.